Literature DB >> 12699420

Low frequency of plasma nerve-growth factor detection is associated with death of memory B lymphocytes in HIV-1 infection.

K Titanji1, A Nilsson, C Mörch, A Samuelsson, A Sönnerborg, S Grutzmeier, M Zazzi, A De Milito.   

Abstract

Nerve growth factor (NGF) regulates B cell activation and differentiation and is an autocrine survival factor for memory B lymphocytes. We have reported recently that the number of memory B cells is reduced during HIV-1 infection. In this study we evaluated whether alteration in the NGF supply was involved in memory B cell loss in HIV-1-infected subjects. High rate of cell death in vitro was observed in memory B cells from HIV-1-infected individuals compared to uninfected donors (26.2 +/- 2.5%versus 7.9 +/- 1.4%, P < 0.001). The increased expression of Fas on memory B cells from infected subjects did not enhance the susceptibility of the cells to Fas-mediated apoptosis in vitro. The frequency of NGF detection in plasma from HIV-1-infected subjects was significantly lower than in healthy donors (33.6%versus 63.6%, P < 0.001). Also, the median plasma NGF in HIV-1-infected individuals was significantly lower than in uninfected controls (5 versus 14 pg/ml, respectively, P < 0.01). Interestingly, the plasma NGF level was correlated directly 1 to the percentage of memory B cells (P < 0.05). HIV-1-infected subjects with a low number of peripheral memory B cells had a reduced incidence of plasmatic NGF (7.4%) compared to patients with a normal level of memory B cells (37%, P < 0.01). Moreover, the addition of recombinant NGF (1 micro g/ml) to cultures of purified B cells reduced cell death of memory B cells from HIV-1-infected subjects from 24.04 +/- 3.0% to 17.4 +/- 1.3% (P < 0.01). HIV-1-infected individuals also carried higher levels of natural anti-NGF autoantibodies compared to uninfected subjects. In conclusion, we found that memory B cells from HIV-1-infected individuals are primed for cell death. Our study suggests an association between low frequency of plasma NGF detection and the increased cell death of memory B lymphocytes observed during HIV-1 infection. Low levels of NGF in plasma may be due to reduced supply or to NGF binding to natural anti-NGF autoantibodies.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12699420      PMCID: PMC1808715          DOI: 10.1046/j.1365-2249.2003.02145.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  38 in total

1.  Human CD4+ T cell clones produce and release nerve growth factor and express high-affinity nerve growth factor receptors.

Authors:  A Lambiase; L Bracci-Laudiero; S Bonini; S Bonini; G Starace; M M D'Elios; M De Carli; L Aloe
Journal:  J Allergy Clin Immunol       Date:  1997-09       Impact factor: 10.793

2.  Quiescent memory B cells in human peripheral blood co-express bcl-2 and bcl-x(L) anti-apoptotic proteins at high levels.

Authors:  F Bovia; A C Nabili-Tehrani; C Werner-Favre; M Barnet; V Kindler; R H Zubler
Journal:  Eur J Immunol       Date:  1998-12       Impact factor: 5.532

3.  Strategies for phenotyping apoptotic peripheral human lymphocytes comparing ISNT, annexin-V and 7-AAD cytofluorometric staining methods.

Authors:  H Lecoeur; E Ledru; M C Prévost; M L Gougeon
Journal:  J Immunol Methods       Date:  1997-12-01       Impact factor: 2.303

Review 4.  The expanding role of nerve growth factor: from neurotrophic activity to immunologic diseases.

Authors:  L Aloe; L Bracci-Laudiero; S Bonini; L Manni
Journal:  Allergy       Date:  1997-09       Impact factor: 13.146

5.  Nerve growth factor is an autocrine factor essential for the survival of macrophages infected with HIV.

Authors:  E Garaci; M C Caroleo; L Aloe; S Aquaro; M Piacentini; N Costa; A Amendola; A Micera; R Caliò; C F Perno; R Levi-Montalcini
Journal:  Proc Natl Acad Sci U S A       Date:  1999-11-23       Impact factor: 11.205

6.  Germinal center B cells rescued from apoptosis by CD40 ligation or attachment to follicular dendritic cells, but not by engagement of surface immunoglobulin or adhesion receptors, become resistant to CD95-induced apoptosis.

Authors:  G Koopman; R M Keehnen; E Lindhout; D F Zhou; C de Groot; S T Pals
Journal:  Eur J Immunol       Date:  1997-01       Impact factor: 5.532

7.  Progressive B cell apoptosis and expression of Fas ligand during human immunodeficiency virus type 1 infection.

Authors:  A Samuelsson; A Sönnerborg; N Heuts; J Cöster; F Chiodi
Journal:  AIDS Res Hum Retroviruses       Date:  1997-08-10       Impact factor: 2.205

8.  Nerve growth factor (NGF) autoantibodies and NGF in the synovial fluid: implications in spondylarthropathies.

Authors:  E Dicou; S Perrot; C J Menkes; C Masson; V Nerriere
Journal:  Autoimmunity       Date:  1996       Impact factor: 2.815

9.  Binding of human immunodeficiency virus type 1 to CD4 and CXCR4 receptors differentially regulates expression of inflammatory genes and activates the MEK/ERK signaling pathway.

Authors:  W Popik; J E Hesselgesser; P M Pitha
Journal:  J Virol       Date:  1998-08       Impact factor: 5.103

10.  Detection of high nerve growth factor serum levels in AIDS-related and -unrelated Kaposi's sarcoma patients.

Authors:  F Pica; A Volpi; G Barillari; M Fraschetti; O Franzese; V Vullo; E Garaci
Journal:  AIDS       Date:  1998-10-22       Impact factor: 4.177

View more
  13 in total

1.  Alterations in peripheral blood B-cell populations in SHIV89.6P-infected macaques (Macacca fascicularis).

Authors:  Heather M Kling; Timothy W Shipley; Karen A Norris
Journal:  Comp Med       Date:  2011-06       Impact factor: 0.982

2.  Highly active anti-retroviral therapy (HAART)-induced maintenance of adaptive but not innate immune parameters is associated with protection from HIV-induced mortality.

Authors:  J Stebbing; M Bower; S Mandalia; M Nelson; B Gazzard
Journal:  Clin Exp Immunol       Date:  2006-08       Impact factor: 4.330

3.  Altered frequency and phenotype of CD4+ forkhead box protein 3+ T cells and its association with autoantibody production in human immunodeficiency virus-infected paediatric patients.

Authors:  R J Argüello; J Balbaryski; G Barboni; M Candi; E Gaddi; S Laucella
Journal:  Clin Exp Immunol       Date:  2012-05       Impact factor: 4.330

Review 4.  Neuroprotective strategies for HIV-1 associated dementia.

Authors:  Huanyu Dou; Jeffrey D Kingsley; R Lee Mosley; Harris A Gelbard; Howard E Gendelman
Journal:  Neurotox Res       Date:  2004       Impact factor: 3.911

Review 5.  HIV-associated memory B cell perturbations.

Authors:  Zhiliang Hu; Zhenwu Luo; Zhuang Wan; Hao Wu; Wei Li; Tong Zhang; Wei Jiang
Journal:  Vaccine       Date:  2015-04-14       Impact factor: 3.641

Review 6.  Mononuclear phagocytes in the pathogenesis of neurodegenerative diseases.

Authors:  I Kadiu; J G Glanzer; J Kipnis; H E Gendelman; M P Thomas
Journal:  Neurotox Res       Date:  2005-10       Impact factor: 3.911

7.  Increased Fas-mediated apoptosis in polymorphonuclear cells from HIV-infected patients.

Authors:  S Salmen; G Terán; L Borges; L Goncalves; B Albarrán; H Urdaneta; H Montes; L Berrueta
Journal:  Clin Exp Immunol       Date:  2004-07       Impact factor: 4.330

8.  A splenic marginal zone-like peripheral blood CD27+B220- B cell population is preferentially depleted in HIV type 1-infected individuals.

Authors:  Matthew Morrow; Antonio Valentin; Richard Little; Robert Yarchoan; George N Pavlakis
Journal:  AIDS Res Hum Retroviruses       Date:  2008-04       Impact factor: 2.205

Review 9.  B cells in HIV infection and disease.

Authors:  Susan Moir; Anthony S Fauci
Journal:  Nat Rev Immunol       Date:  2009-04       Impact factor: 53.106

10.  Abnormal B cell memory subsets dominate HIV-specific responses in infected individuals.

Authors:  Lela Kardava; Susan Moir; Naisha Shah; Wei Wang; Richard Wilson; Clarisa M Buckner; Brian H Santich; Leo J Y Kim; Emily E Spurlin; Amy K Nelson; Adam K Wheatley; Christopher J Harvey; Adrian B McDermott; Kai W Wucherpfennig; Tae-Wook Chun; John S Tsang; Yuxing Li; Anthony S Fauci
Journal:  J Clin Invest       Date:  2014-06-02       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.